Skip to main content
Quest Diagnostics

Multimodal Analysis of a Rare BARD1 Missense Variant Suggests Its Pathogenicity Is Conditional

Multimodal Analysis of a Rare BARD1 Missense Variant Suggests Its Pathogenicity Is Conditional

Authors: Chan-Pak-Choon F, Gao Y, Camacho-Valenzuela J, Cabré-Romans JJ, Minju-Op A, Fu L, Polak P, Rivera B, Cuella-Martin R, Foulkes WD

Citation: NPJ Breast Cancer. 2026 Apr 21. doi: 10.1038/s41523-026-00955-8. Online ahead of print.

Specialties: Oncology, Women's health, OB/GYN, Genetics

Related content

Publication
Probing the Relevance of BRCA1 and BRCA2 Germline Pathogenic Variants Beyond Breast and Ovarian Cancer
Publication
The Effect of a Digital Health Coaching Program on Patient-Reported and Healthcare Utilization Outcomes of Women With Breast Cancer
Test FAQ
BRCA1 and BRCA2 tests
Test FAQ
BRCA Panel Plus
Publication
Tracking Response to Neoadjuvant Systemic Therapy Through Circulating Tumor DNA Analysis in Breast Cancer
Audio Podcast
Enhancing Cancer Treatment Decisions With Ultrasensitive MRD Testing
Audio Podcast
Exploring Digital Pathology and Artificial Intelligence
Publication
Multicenter Evaluation of 2 Vaginal Self-Collection Devices for HPV Testing

Our company

Quest® is the brand name used for services offered by Quest Diagnostics Incorporated and its affiliated companies. Quest Diagnostics Incorporated and certain affiliates are CLIA-certified laboratories that provide HIPAA-covered services.  Other affiliates operated under the Quest® brand, such as Quest Consumer Inc., do not provide HIPAA-covered services. 

 

Quest®, Quest Diagnostics®, any associated logos, and all associated Quest Diagnostics registered or unregistered trademarks are the property of Quest Diagnostics. All third-party marks—® and ™—are the property of their respective owners. © 2026 Quest Diagnostics Incorporated. All rights reserved. Image content features models and is intended for illustrative purposes only.